| HEIDELBERG PHARMA AG O.N. |
| Deutschland |
| Gesundheit |
| DE000A11QVV0 / A11QVV |
| HPHA (Frankfurt) |
| FRA:HPHA, ETR:HPHA, HPHA:GR |
| - |
| https://heidelberg-pharma.. |
|
Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in oncology, developing innovative antibody-drug conjugates (ADCs) for targeted cancer therapies. Its primary focus is on creating novel drugs that combine the specificit..
>Volltext.. |
| 118.24 Mio. EUR |
| 146.18 Mio. EUR |
| 7.43 Mio. EUR |
| -31.54 Mio. EUR |
| -33.05 Mio. EUR |
| -0.71 EUR |
| 52.83 Mio. EUR |
| 24.89 Mio. EUR |
| -24.76 Mio. EUR |
| 3.48 |
| 77.97% |
| -42.02% |
| - |
| - |
| - |
| - |
| HEIDELBERG PHARMA, WILEX |
| 26.08.26 |
|